(Q34362277)

1 August 2017

title

Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population (English)

1 reference

1 August 2017

0 references

1 reference

T Rusdiana

1

1 reference

1 August 2017

T Araki

2

1 reference

1 August 2017

T Nakamura

3

1 reference

1 August 2017

A Subarnas

4

1 reference

1 August 2017

K Yamamoto

5

1 reference

1 August 2017

publication date

2 August 2012

1 reference

European Journal of Clinical Pharmacology

1 August 2017

published in

1 reference

1 August 2017

volume

69

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

395-405

1 reference

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Association of warfarin dose with genes involved in its action and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Quantification of total and free concentrations of R- and S-warfarin in human plasma by ultrafiltration and LC-MS/MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Human P450 metabolism of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

CYP4F2 genetic variant alters required warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Ranitidine-warfarin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1356-9

Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22855348

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Decreased hypoprothrombinemic effect of warfarin associated with furosemide

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22855348

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00228-012-1356-9

1 reference

Dimensions Publication ID

1 August 2017

1038702269

0 references

1 reference